Drug–Drug Interactions of Newly Approved Direct|Acting Antiviral

Drug-Drug Interactions With Antiviral Agents in People Who Inject ...

Conclusion: Integrase inhibitors may be safely coadministered with opioid-replacement therapy. With respect to HCV DAAs, most currently approved and late-stage ...

Comedications and potential drug-drug interactions with direct ...

cytochrome P450; DAAs, direct-acting antivirals; DDIs, drug-drug interactions; ... approved for hepatitis C virus (HCV) treatment in patients.

Potential for Drug-Drug Interactions between Antiretrovirals ... - PLOS

Development of direct acting antivirals (DAA) offers new benefits for patients with chronic hepatitis C. The combination of these drugs with antiretroviral ...

Direct-acting antivirals for the treatment of hepatitis C virus infection

Direct-acting antivirals for the treatment of hepatitis C virus infection. Formulary drug information for this topic. No drug references ...

Effectiveness and potential drug interactions in antiviral therapy for ...

In 2015, the drugs of the new generation of direct-acting antivirals were incorporated: sofosbuvir, simeprevir and daclastavir (Mesquita et al.,. 2016; Brasil, ...

Targeting Hepatitis C With Direct-Acting Antivirals - U.S. Pharmacist

There are new medications called combination direct-acting antivirals that can be utilized for HCV. ... drug-drug interactions that may ...

Monitoring Patients Who Are Starting HCV Treatment, Are on ...

Assessment of potential drug-drug interactions with concomitant medications is recommended prior to starting DAA therapy and, when possible, an ...

Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir

To assess drug-drug interaction (DDI) potential for the three direct-acting antiviral (3D) regimen of ombitasvir, dasabuvir, and paritaprevir, in vitro studies

Drug-Drug Interactions between Antiretrovirals and Other Drugs | NIH

Pharmacokinetic (PK) drug–drug interactions between antiretroviral (ARV) drugs and concomitant medications are common and may lead to increased or decreased ...

Evaluation of Drug Interactions in Patients Treated with DAAs for ...

Since oral DAAs have different DDIs profiles, hepatologists should prefer the antiviral DAA combination presenting the lowest instance of ...

Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in ...

(an NS5A inhibitor) and dasabuvir (a nonnucleoside polymerase inhibitor) was recently approved by the US Food and Drug Administration. This fixed- dose ...

Navigating Clinically Significant Drug Interactions Between Hepatitis ...

Navigating Clinically Significant Drug Interactions Between Hepatitis C Direct Acting Antiviral Agents and Statins ; Glecaprevir (300 mg)/Pibrentasvir (120 mg) ...

A clinician's guide to drug‐drug interactions with direct ... - LWW

The US Food and Drug Administration has recently approved a number of new direct-acting antiviral agents for the treatment of chronic ...

Prevalence of Potential Drug Interactions With Direct-Acting ...

Contemporary treatment for coronavirus disease 2019 (COVID-19) includes direct-acting antivirals (DAAs). We sought to characterize patients' characteristics, ...

Effectiveness and potential drug interactions in antiviral therapy for ...

Direct-acting antivirals used in the treatment of hepatitis C have demonstrated high rates of efficacy, are well tolerated and considered safe.

A clinician's guide to drug-drug interactions with direct-acting ...

In this review we summarize the available data regarding drug-drug interactions for direct-acting antiviral agents, the interactions being the most clinically ...

A clinician's guide to drug‐drug interactions with direct‐acting ...

The US Food and Drug Administration has recently approved a number of new direct‐acting antiviral agents for the treatment of chronic hepatitis C virus that ...

Drug Interactions with the Direct-Acting Antiviral Combination of ...

The two direct-acting antiviral (2D) regimen of ombitasvir and paritaprevir (administered with low-dose ritonavir) is being developed for treatment of ...

Drug-drug interactions between antithrombotics and direct-acting ...

Ticagrelor is a weak inhibitor of CYP3A4 and could increase the exposure of drugs with a narrow therapeutic range (Zhou et al., 2011). There are ...

Reported adverse events related to use of hepatitis C virus direct ...

Due to concerns over potential interactions between some hepatitis C direct-acting antivirals (DAAs) and opioids, we describe adverse event ...